Abstract:Background Although there is an ever growing number of adult patients with congenital heart disease (ACHD), many are still afflicted by premature death. Previous reports suggested that natriuretic peptides may identify ACHD patients with adverse outcome. We investigated the prognostic power of brain natriuretic peptide (BNP) across the spectrum of ACHD in a large contemporary cohort. Methods We retrospectively studied 3,392 consecutive and well-characterised ACHD patients under long-term follow-up at a tertiary ACHD centre between 2006-2019. The primary study endpoint was all-cause mortality. Results A total of 11,974 BNP measurements were analysed. The median BNP at baseline was 47 [24-107] ng/L. During a median follow-up of 8.6 years (29,115 patient-years), 615 (18.1%) patients died. On univariate and multivariate analysis both baseline BNP and temporal changes in BNP levels were predictive of mortality (p<0.001 for both) independent of congenital heart disease diagnosis, complexity, anatomic/haemodynamic features, and/or systolic systemic ventricular function. Patients within the highest quartile of baseline BNP (>107 ng/L) and those within the highest quartile of temporal BNP change (>35 ng/L) had 5.8 and 3.6-fold increased risk of death, respectively. Conclusion Baseline BNP and temporal BNP changes are both significantly associated with all-cause mortality in ACHD independent of congenital heart disease diagnosis, complexity, anatomic/haemodynamic features, and/or systolic systemic ventricular function. BNP levels represent an easy to obtain and inexpensive marker conveying prognostic information and should be used for the routine surveillance of patients with ACHD. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement no external funding was received ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Institutional Research and Governance Committee at Royal Brompton Hospital, London, UK. As this was a retrospective analysis based on data collected for routine clinical care and administrative purposes (UK National Research Ethics Service guidance), individual informed consent was not required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data that support the findings of this study are available from the first author YY, upon reasonable request.

Association Between BNP and All-Cause Mortality in Critically Ill Children: a Cohort Study

BNP levels and its influencing factors in patients with acute coronary syndrome

Prognostic Value of B-type Natriuretic Peptide (BNP) and Its Potential Role in Guiding Fluid Therapy in Critically Ill Septic Patients

B-type Natriuretic Peptide Levels Predict Long-Term Mortality in a Large Cohort of Adults with Congenital Heart Disease.

Correlation Between Early Brain Natriuretic Peptide Level and Mortality in Cancer Patients with Septic Shock.

Associations Between Elevated Systolic Blood Pressure and Outcomes in Critically Ill Patients: A Retrospective Cohort Study and Propensity Analysis

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Prognostic role of BNP in children undergoing surgery for congenital heart disease: analysis of prediction models incorporating standard risk factors

Abstracts for the British Congenital Cardiac Association Annual Meeting: The Barbican, London, 24–25 November 2005: Winner of the Young Investigator's Prize: B-Type Natiuretic Peptide (BNP) as a marker of paediatric heart failure

Value of cardiac enzyme spectrum for the risk assessment of mortality in critically ill children: a single-centre retrospective study

Baseline and Serial BNP Measurements Predict Long-Term Mortality in Adults with Congenital Heart Disease: A study including 3,392 patients

NT‐proBNP and All‐Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study

Association of N-terminal pro-B-type natriuretic peptide levels and mortality risk in acute myocardial infarction across body mass index categories: an observational cohort study

NT-proBNP point-of-care testing for predicting mortality in end-stage renal disease: A survival analysis

Study of serum NT-proBNP levels and warning mechanism in common diseases of neonates

Elevated BUN Upon Admission as a Predictor of in-Hospital Mortality Among Patients with Acute Exacerbation of COPD: A Secondary Analysis of Multicenter Cohort Study

Association of N-terminal pro-B natriuretic peptide with all-cause mortality and cardiovascular mortality in obese and non-obese populations and the development of a machine learning prediction model: National Health and Nutrition Examination Survey (NHANES) 1999-2004

The association of blood urea nitrogen levels upon emergency admission with mortality in acute exacerbation of chronic obstructive pulmonary disease

Relationship between B-type natriuretic peptide and prognosis of stent implantation in elderly patients

[Prognostic Value of N-terminal B-type Natriuretic Peptide on All-Cause Mortality in Heart Failure Patients with Preserved Ejection Fraction].

Clinical significance of plasma BNP in the evaluation of AECOPD